Abstract:Objective: To investigate the current trend of breast cancer neoadjuvant therapy and provide reference for the improvement of breast cancer clinical guideline in the future. Methods: Questionnaires of cross-sectional survey were sent to 110 hospitals (breast cancer surgery quantity surpassing 200) between July 2018 and September 2018. The stages and subtypes, therapeutic regimen, treatment assession, operation choice and preforming of patients underwent neoadjuvant therapy were recorded. Results: Neoadjuvant treatment has been performed in all of the 110 hospitals. The total number of breast patients underwent neoadjuvant therapy was about 14 550 (17.0% in surgical patients) in 2017. For all of the neoadjuvant patients, the proportion of stageⅡ patients was less than 30% in 81 hospitals, and the proportion of stage Ⅲ was more than 50% in 84 hospitals. The numbers of estrogen receptor (ER) (+ )/human epidermal growth factor receptor-2 (HER-2) (-), ER (-)/HER-2 (+ ) and triple negative subtype breast cancer patients were 3 550 (24.4%), 6 024 (41.4%) and 4 991 (34.3%), respectively. Patient's scruples of relatively delayed operation and weak will of breast conservation after neoadjuvant therapy were the majority reasons for neoadjuvant therapy restriction. Anthracycline followed by taxane was the most usual neoadjuvant therapeutic regimens in 53.6% hospitals, and anthracycline plus taxane was the first choice in 42.7% hospitals. Chemotherapy with targeting therapy was recommended to HER-2 positive neoadjuvant patients in 80.9% hospitals. To assess treatment outcome of neoadjuvant treatment, 42.7% hospitals used MRI in more than 50% patients while the usage rate of MRI was less than 20% in 37.3% hospitals. The proportions of hospital using repeat-marking, tattoo and metal clip as the first method to identify the primary tumor region and lymph nodes were 60.0%, 29.1% and 10.9%, respectively. Breast-conservation rate after neoadjuvant therapy was less than 20% in 87.3% hospitals. Conclusions: Neoadjuvant therapy for breast cancer is widely performed in most hospitals in China, while the proportion of neoadjuvant treatment in patients with operable breast cancer is still low. Meanwhile, the idea of achieving de-escalation operation through neoadjuvant treatment is not promoted and the therapeutic evaluation method of neoadjuvant treatment needs further studies to improve.

Clinical observation of neoadjuvant chemotherapy on 86 breast cancer patients

Effects of Core Needle Biopsy and Subsequent Neoadjuvant Chemotherapy on Molecular Alterations and Outcome in Breast Cancer

Clinical Analysis of Neoadjuvant Chemotherapy for 40 Cases of Breast Cancer Cases

Effect of neoadjuvant chemotherapy on histopathology and immunohistochemistry in breast cancer

Clinical Efficacy Observations of Neoadjuvant Therapy with TCH Regimen in Treatment of Her-2-overexpressing Breast Cancer

Assessment of neoadjuvant chemotherapy for breast cancer in 40 patients

Clinical Effect of Breast Conserving Surgery Combined with Neoadjuvant Chemotherapy Treatment for Breast Cancer

Relationship Between Tumor Markers, ER/PR, HER2, Ki67 and CyclinA2 and Clinical Efficacy of Neoadjuvant Chemotherapy

Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer]

Clinical research of utilizing Ki67 in predicting the effect of neoadjuvant chemotherapy on breast cancer

Relationship of peripheral blood circulating tumor cells with therapeutic effect of neoadjuvant chemotherapy in breast cancer:report of 70 cases

Efficacy of Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer and Prognostic Analysis

Expression of ER, PR, HER-2, Ki-67 Before and after Neoadjuvant Chemotherapy and the Relation Between Their Expression and the Curative Effects of Neoadjuvant Chemotherapy in Breast Cancer

Clinical Observation of Neoadjuvant Chemotherapy and Operation for Patients with Non-small Cell Lung Cancer

Clinical Efficacy of Neoadjuvant Chemotherapy Combined with Trastuzumab for HER-2 Positive Breast Cancer

Clinical Evaluation of Neoadjuvant Chemotherapy with Docetaxel for Breast Cancer

<TITLE>CLINICAL ANALYSIS OF PRE-OPERATIVE NEOADJUVANT CHEMOTHERAPY IN ELDERLY PATIENTS WITH ADVANCED BREAST CANCER

Analysis on the factors related with the response of neoadjuvant therapy in primary breast cancer

Effect of Neoadjuvant Chemotherapy on Breast Conservative Surgery of Breast Cancer

Analysis of Neoadjuvant Docetaxel, Carboplatin and Trastuzumab (TCH) in HER-2-positive Breast Cancer

[Current Trend of Breast Cancer Neoadjuvant Treatment in China: a Cross-Sectional Study].